Audrey Odom, MD, PhD, looks at a microscope slide of malaria parasites. Odom and her colleagues have found one way the malaria parasite becomes resistant to fosmidomycin, an antimalarial drug in clinical trials.
The research team also defined the crystal structure of the PfHAD1 protein, above. When PfHAD1 is dysfunctional, the malaria parasite is resistant to fosmidomycin, an antibiotic in clinical trials for the treatment of malaria.